Johnson & Johnson announced positive results from the Phase 3 MARIPOSA-2 study, showing RYBREVANT combined with chemotherapy led to significant and sustained improvement in post-progression outcomes for patients with previously treated EGFR-mutated non-small cell lung cancer.